Skip to main content

How Dokumeds is moving towards digitalization

The CRO Dokumeds has chosen BSI as its CTMS partner. In an interview, Dokumeds CEO, Indra Aboltina, explained how the company is moving towards digitalization.

How will the introduction of CTMS improve the collaboration between Dokumeds and its sponsors?

For the currently used management tools, information must be gathered from various sources and systems involved in clinical trial management, which is time consuming. By launching CTMS we are improving oversight of trial performance, providing quick and easy access to actual versus target milestone comparisons across the site, trial and company levels. Comprehensive reports in CTMS provide an overview of information that facilitates early risk identification and emphasis on focus areas to ensure delivery of the expected results and milestone attainment.


Which role does CTMS play in the context of CRO-pharma collaboration?

Introducing a robust system to manage clinical trials enables Dokumeds to improve its service and quality. Data transparency, interaction and easy trial progress control and the option of providing sponsor access to the operational data will all benefit the Dokumeds-sponsor collaboration.

How was the CRO-pharma collaboration previously organized?

While the existing clinical trial management tools enable gathering of the required data and trial progress control, there is improvement potential in terms of resource effectiveness. Implementing a system for clinical trial management tailored to Dokumeds’ needs provides added value to Dokumeds’ services, making them more attractive to sponsor companies. With the CRO CTMS platform it is possible to provide the sponsor access to the operational data.


What is Dokumeds trying to achieve?

Dokumeds aims to maintain and increase its present business volume by providing operational flexibility. Introduction of CTMS and tools streamlining online and offline data exchanges improves the generation and handling of data, documents, as well as providing timely access to accurate and up-to-date information.


What opportunities and challenges do you have?

Managing trial timelines and compliance with the milestones can be challenging without an effective reporting system. Having all trial-related data in CTMS enables easy tracking of timelines and achievement of the milestones, providing the project manager and company management the oversight needed to direct attention and allocate resources towards areas of risk.


What business benefits does Dokumeds expect to attain with the new system?

Real-time oversight of trial progress, issues and possibilities permits more efficient trial planning and conduct. The input of each team member is essential for reaping the benefits that the system has to offer.

CTMS User Group Meeting in Zurich

We are pleased to have a growing customer base in the CTMS field. The cooperation and close exchange with our customers are driving the product forward and contributing to the professionalization and boosting of efficiency for the entire industry. We will introduce the new BSI CTMS Standard 5.6 together with Dokumeds at the CTMS User Group Meeting on November 16-17, 2016 at the Gottlieb Duttweiler Institute in Zurich. The product roadmap for 2017 will be discussed and coordinated together with many existing and potentially new BSI CTMS customers. It is essential to involve customers in the definition of the future functionalities of the CTMS. It is also a great opportunity for the BSI CTMS customer community to share their knowhow and experiences.

Next Best Action:

BSI Life Sciences



Jan Nielsen
BSI Life Sciences Community Manager

+41 58 255 96 22